News
Telehealth Leader Investing to Serve Patients, Doctors, Hospitals and Payers During COVID-19 Crisis
Amwell®, a national telehealth leader, announced it has closed its Series C financing round, adding $194 million in funding across two tranches. Many early investors and strategic partners participated in this round, including Allianz X and Takeda. Amwell will use significant parts of the funds to expand its investment in technology and services that make it easy, convenient and effective for doctors and patients to connect securely at scale. Amwell will continue to ensure that clinical encounters remain fully integrated in existing workflows and enveloped with healthcare-appropriate clinical and administrative information, management, and reporting.
As COVID-19 swept across the United States, Amwell has seen a significant expansion in usage of its core Amwell Platform. With fewer regulatory restrictions as well as enhanced reimbursement from both Medicare and Commercial insurance, Amwell has seen:
- Growth in on-demand visits for COVID-19 symptoms and/or risk assessments, as well as for referrals as needed to hospital or testing facilities.
- Significantly higher scheduled visit volume, as providers seek to treat patients, especially the elderly or those with underlying health conditions, for prescription renewals, specialty visits, and regular primary care check-ins during State-issued “stay at home” orders.
As a result of these developments, Amwell has recently facilitated as many as 45,000 telehealth visits per day across the Amwell Platform. Relatedly, the number of Active Providers, clinicians who have completed at least one visit in the past year, has risen significantly.
“The past two months have accelerated telehealth by more than two years,” said Ido Schoenberg, CEO of Amwell. “We intend to build upon this momentum to transform healthcare with digital care delivery. Our strategic investors are providers, insurers, consumer gateways and healthcare innovators. Each of these partners play a key role in creating a more interconnected digital healthcare ecosystem, where our mission is to deliver greater access to more affordable, high quality care.”
“Being an investor and partner to Amwell since early 2018, Allianz is excited to see the company emerge as a digital healthcare leader in the U.S.” said Nazim Cetin, CEO of Allianz X. “As one of the leading insurance and financial services leaders in the world, we look forward to deepening our collaboration and bringing innovative solutions to a global audience.”
“Takeda is investing in digital transformation across our business and building key technology partnerships,” said Karl Hick, Chief Digital & Information Officer at Takeda. “Patient journeys will be transformed through new settings of care as we emerge from COVID-19. Amwell has developed a highly scalable and agile technology platform that we believe can directly improve patient access and outcomes.”
About Amwell
Amwell is a leading telehealth platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that digital care delivery will transform healthcare. The Company offers a single, comprehensive platform to support all telehealth needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With over a decade of experience, Amwell powers telehealth solutions for over 240 health systems comprised of 2,000 hospitals and 55 health plan partners with over 36,000 employers, reaching over 150 million lives. For more information please visit https://business.amwell.com/.
American Well, Amwell, and The Exchange are registered trademarks or trademarks of American Well Corporation in the United States and other countries. All other trademarks used herein are the property of their respective owners.
- Originally published at https://business.amwell.com June 10, 2020.